1061 related articles for article (PubMed ID: 17950653)
21. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia.
Webster MK; Donoghue DJ
EMBO J; 1996 Feb; 15(3):520-7. PubMed ID: 8599935
[TBL] [Abstract][Full Text] [Related]
22. Achondroplasia.
Baujat G; Legeai-Mallet L; Finidori G; Cormier-Daire V; Le Merrer M
Best Pract Res Clin Rheumatol; 2008 Mar; 22(1):3-18. PubMed ID: 18328977
[TBL] [Abstract][Full Text] [Related]
23. Mutant activated FGFR3 impairs endochondral bone growth by preventing SOX9 downregulation in differentiating chondrocytes.
Zhou ZQ; Ota S; Deng C; Akiyama H; Hurlin PJ
Hum Mol Genet; 2015 Mar; 24(6):1764-73. PubMed ID: 25432534
[TBL] [Abstract][Full Text] [Related]
24. A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor 3.
Wang Y; Spatz MK; Kannan K; Hayk H; Avivi A; Gorivodsky M; Pines M; Yayon A; Lonai P; Givol D
Proc Natl Acad Sci U S A; 1999 Apr; 96(8):4455-60. PubMed ID: 10200283
[TBL] [Abstract][Full Text] [Related]
25. Co-occurrence of achondroplasia and Down syndrome: Genotype/phenotype association.
de Azevedo Moreira LM; Matos MA; Schiper PP; Carvalho AF; Gomes IC; Rolemberg JC; Ferreira de Lima RL; Toralles MB
Birth Defects Res A Clin Mol Teratol; 2010 Apr; 88(4):228-31. PubMed ID: 20222028
[TBL] [Abstract][Full Text] [Related]
26. Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model.
Komla-Ebri D; Dambroise E; Kramer I; Benoist-Lasselin C; Kaci N; Le Gall C; Martin L; Busca P; Barbault F; Graus-Porta D; Munnich A; Kneissel M; Di Rocco F; Biosse-Duplan M; Legeai-Mallet L
J Clin Invest; 2016 May; 126(5):1871-84. PubMed ID: 27064282
[TBL] [Abstract][Full Text] [Related]
27. Typical achondroplasia secondary to a unique insertional variant of FGFR3 with in vitro demonstration of its effect on FGFR3 function.
Meyer AN; Modaff P; Wang CG; Wohler E; Sobreira NL; Donoghue DJ; Pauli RM
Am J Med Genet A; 2021 Mar; 185(3):798-805. PubMed ID: 33368972
[TBL] [Abstract][Full Text] [Related]
28. FGFR3 mutation causes abnormal membranous ossification in achondroplasia.
Di Rocco F; Biosse Duplan M; Heuzé Y; Kaci N; Komla-Ebri D; Munnich A; Mugniery E; Benoist-Lasselin C; Legeai-Mallet L
Hum Mol Genet; 2014 Jun; 23(11):2914-25. PubMed ID: 24419316
[TBL] [Abstract][Full Text] [Related]
29. Clinical dosage of meclozine promotes longitudinal bone growth, bone volume, and trabecular bone quality in transgenic mice with achondroplasia.
Matsushita M; Esaki R; Mishima K; Ishiguro N; Ohno K; Kitoh H
Sci Rep; 2017 Aug; 7(1):7371. PubMed ID: 28785080
[TBL] [Abstract][Full Text] [Related]
30. FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway.
Matsushita T; Wilcox WR; Chan YY; Kawanami A; Bükülmez H; Balmes G; Krejci P; Mekikian PB; Otani K; Yamaura I; Warman ML; Givol D; Murakami S
Hum Mol Genet; 2009 Jan; 18(2):227-40. PubMed ID: 18923003
[TBL] [Abstract][Full Text] [Related]
31. FGF upregulates osteopontin in epiphyseal growth plate chondrocytes: implications for endochondral ossification.
Weizmann S; Tong A; Reich A; Genina O; Yayon A; Monsonego-Ornan E
Matrix Biol; 2005 Dec; 24(8):520-9. PubMed ID: 16253490
[TBL] [Abstract][Full Text] [Related]
32. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia.
Naski MC; Wang Q; Xu J; Ornitz DM
Nat Genet; 1996 Jun; 13(2):233-7. PubMed ID: 8640234
[TBL] [Abstract][Full Text] [Related]
33. Novel phenotype of achondroplasia due to biallelic FGFR3 pathogenic variants.
Chang IJ; Sun A; Bouchard ML; Kamps SE; Hale S; Done S; Goldberg MJ; Glass IA
Am J Med Genet A; 2018 Jul; 176(7):1675-1679. PubMed ID: 30160829
[TBL] [Abstract][Full Text] [Related]
34. Clinical and molecular characteristics of Thai patients with achondroplasia.
Shotelersuk V; Ittiwut C; Srivuthana S; Wacharasindhu S; Aroonparkmongkol S; Mutirangura A; Poovorawan Y
Southeast Asian J Trop Med Public Health; 2001 Jun; 32(2):429-33. PubMed ID: 11556601
[TBL] [Abstract][Full Text] [Related]
35. FGFR3 gene mutation plus GRB10 gene duplication in a patient with achondroplasia plus growth delay with prenatal onset.
Yuan H; Huang L; Hu X; Li Q; Sun X; Xie Y; Kong S; Wang X
Orphanet J Rare Dis; 2016 Jul; 11(1):89. PubMed ID: 27370225
[TBL] [Abstract][Full Text] [Related]
36. Gain-of-function mutation in FGFR3 in mice leads to decreased bone mass by affecting both osteoblastogenesis and osteoclastogenesis.
Su N; Sun Q; Li C; Lu X; Qi H; Chen S; Yang J; Du X; Zhao L; He Q; Jin M; Shen Y; Chen D; Chen L
Hum Mol Genet; 2010 Apr; 19(7):1199-210. PubMed ID: 20053668
[TBL] [Abstract][Full Text] [Related]
37. Mutant FGFR3 associated with SADDAN disease causes cytoskeleton disorganization through PLCγ1/Src-mediated paxillin hyperphosphorylation.
Montone R; Romanelli MG; Baruzzi A; Ferrarini F; Liboi E; Lievens PM
Int J Biochem Cell Biol; 2018 Feb; 95():17-26. PubMed ID: 29242050
[TBL] [Abstract][Full Text] [Related]
38. Restrained chondrocyte proliferation and maturation with abnormal growth plate vascularization and ossification in human FGFR-3(G380R) transgenic mice.
Segev O; Chumakov I; Nevo Z; Givol D; Madar-Shapiro L; Sheinin Y; Weinreb M; Yayon A
Hum Mol Genet; 2000 Jan; 9(2):249-58. PubMed ID: 10607835
[TBL] [Abstract][Full Text] [Related]
39. [From gene to disease; achondroplasia and other skeletal dysplasias due to an activating mutation in the fibroblast growth factor].
van Ravenswaaij-Arts CM; Losekoot M
Ned Tijdschr Geneeskd; 2001 Jun; 145(22):1056-9. PubMed ID: 11414167
[TBL] [Abstract][Full Text] [Related]
40. [Clinical features and
Zhang HQ; Tao DY; Zhang JJ; Niu HH; Luo JF; Cheng SQ
Zhongguo Dang Dai Er Ke Za Zhi; 2022 Apr; 24(4):405-410. PubMed ID: 35527416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
